Search Results - "Java J"

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Authors: Tewari, K. S. Java, J. J. Eskander, R. N. et al.

Source: Annals of Oncology. Jan2016, Vol. 27 Issue 1, p114-121. 8p. 3 Charts, 2 Graphs.

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study.

Authors: Rose, P.G. Java, J. Morgan, M.A. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p207-208. 2p.

Nomogram predicting individual survival following recurrence in advanced stage high-grade ovarian cancer from NRG Oncology/Gynecologic Oncology Group randomized trials of platinum and paclitaxel.

Authors: Rose, P.G. Java, J. O'Malley, D.M. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p61-61. 1p.

Significance of risk-weighted surgical-pathological factors on survival of stage IB cervical cancer: An ancillary analysis of Gynecologic Oncology Group study.

Authors: Matsuo, K. Java, J. Muderspach, L.I. et al.

Source: Gynecologic Oncology. Jun2016 Supplement 1, Vol. 141, p22-22. 1p.

Patterns of crossover to antiangiogenesis agents in recurrent ovarian cancer patients: An analysis of a Gynecologic Oncology Group ancillary data study (GOG#218, abstract).

Authors: Java, J. Monk, B. Coleman, R. et al.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe122-e122. 1p.

Survival in early stage endometrioid endometrial cancer risk groups: A Gynecologic Oncology Group ancillary data study.

Authors: Java, J. Parker, L. Metzinger, D. et al.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe23-e23. 1p.

Negative survival impact associated with >25 day interval from surgical cytoreduction to initiation of systemic therapy in advanced ovarian carci- noma: A Gynecologic Oncology Group ancillary data study.

Authors: Java, J. Tewari, K. Burger, R. et al.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe22-e23. 0p.

Pathologic and treatment outcomes among a geriatric population of endometrial cancer patients: A Gynecologic Oncology Group ancillary data study.

Authors: Java, J. Moore, K. Walker, J.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe19-e19. 1p.

Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study.

Authors: Java, J. Salani, R. Armstrong, D. et al.

Source: Gynecologic Oncology. Jul2013, Vol. 130 Issue 1, pe4-e4. 1p.

The prognostic significance of pre and post-treatment CA-125 levels in low grade serous ovarian carcinoma: A Gynecologic Oncology Group study

Authors: Fader, A. Nickles Java, J. Tergas, A. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS35-S36. 0p.

A practical prediction model for determining bevacizumab response and toxicity in the treatment of advanced ovarian and peritoneal cancers – An analysis of GOG 218

Authors: Chan, J. Java, J. Monk, B. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS31-S31. 1p.

Does maintaining adjuvant chemotherapy dose intensity have an impact on the outcome of treatment in ovarian cancer patients?: A Gynecologic Oncology Group study

Authors: Olawaiye, A. Java, J. Krivak, T. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS25-S25. 1p.

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Authors: Landrum, L. Java, J. Mathews, C. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS24-S25. 0p.

Optimal cytoreductive surgery to microscopic residual improves survival in women with low grade serous ovarian carcinoma: A Gynecologic Oncology Group ancillary study

Authors: Nickles Fader, A. Java, J. Ueda, S. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS12-S13. 0p.

Incidence of nodal metastasis in endometrioid endometrial cancer risk groups: A Gynecologic Oncology Group multicenter review

Authors: Milam, M. Java, J. Walker, J. et al.

Source: Gynecologic Oncology. Mar2011 Supplement 1, Vol. 120, pS4-S4. 1p.

Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers.

Authors: Mysona, D.P. Tran, L.K.H. Tran, P.M.H. et al.

Source: Gynecologic Oncology. Jan2020, Vol. 156 Issue 1, p77-84. 8p.

A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.

Authors: Previs, R.A. Bevis, K.S. Huh, W. et al.

Source: Gynecologic Oncology. Mar2014, Vol. 132 Issue 3, p531-536. 6p.

Prognostic factors predictive of response to bevacizumab combined with chemotherapy in recurrent ovarian cancer – A multi-institutional study

Authors: Alvarez-Secord, A. Huh, W. Tillmanns, T. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS98-S99. 0p.

Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemotherapy: a multicenter comparison between specialized dentists and registered nurses.

Authors: Ibrahim A Mahmoud D Mavandadipur H et al.

Source: BMC cancer [BMC Cancer] 2025 Dec 17; Vol. 25 (1), pp. 1874. Date of Electronic Publication: 2025 Dec 17.

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Comparative Study; Clinical Trial, Phase III

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Understanding rare genetic variants within the terminal pathway of complement system in preeclampsia.

Authors: Lokki AI Triebwasser M Daly E et al.

Corporate Authors: Lokki AI Triebwasser M Daly E et al.

Source: Genes and immunity [Genes Immun] 2025 Feb; Vol. 26 (1), pp. 22-26. Date of Electronic Publication: 2024 Dec 17.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 100953417 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5470 (Electronic) Linking ISSN: 14664879 NLM ISO Abbreviation: Genes Immun Subsets: MEDLINE